Sanofi, Regeneron gets USFDA approval for cholesterol drug Praluent
The USFDA's decision will allow the Praluent, developed along with Sanofi SA, to be prescribed in reducing the overall risk of major adverse cardiovascular events (MACE).
U.S: The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent, as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
The FDA's decision will allow the drug, developed along with Sanofi SA, to be prescribed in reducing the overall risk of major adverse cardiovascular events (MACE).
MACE is an umbrella term that includes heart attack, ischemic stroke, death from coronary heart disease and unstable chest pains requiring hospitalization.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here